title: Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer.
abstract: BACKGROUND
  Peroxiredoxin-1 (Prx-1) is an important protector for redox damage and its abnormal expression is continually reported in various tumors. This study aims to investigate the expression status of Prx-1 and evaluate its clinical value in pancreatic cancer.
  
  
  METHODS
  Immunohistochemistry was used to detect Prx-1 expression in pancreatic cancer tissues and para-cancerous tissues. Enzyme-linked immunosorbent assay (ELISA) method was applied to detect the serum Prx-1 levels.
  
  
  RESULTS
  The immunohistochemical results indicated that positive rate of Prx-1 was (p < 0.05) higher in pancreatic cancer tissues (74.4%) than in para-cancerous tissues (37.2%). Prx-1 expression was positively correlated with vascular endothelial growth factor (VEGF) and microvessel density (MVD) in cancer tissues. The ELISA results showed that patients with pancreatic cancer had a higher serum Prx-1 level than healthy subjects (31.2 ± 13.5 vs. 13.2 ± 11.9 ng/ml, p < 0.001). Prx-1 expression was correlated with aggressive clinicopathological parameter. The combination of serum Prx-1 and CA19-9, the area under the curve (AUC) was significantly higher than Prx-1 separate. Positive Prx-1 expression was correlated with disappointing overall survival (OS) (p = 0.002) and disease-free survival (DFS) (p < 0.001). Multivariate analysis showed that Prx-1 staining as an independent biomarker of poor OS (p = 0.035) and DFS (p < 0.001).
  
  
  CONCLUSIONS
  These findings suggest that the levels of Prx-1 expression are significantly increased in pancreatic cancer. The up-regulated Prx-1 is closely related to tumor angiogenesis and acts as a promising tumor marker for diagnosis and prognosis of pancreatic cancer.
authors.affiliation: Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China.
authors.forename: C-Y
authors.initials: CY
authors.lastname: Cai
authors.affiliation: Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China. Electronic address: jackyzhai123@163.com.
authors.forename: L-L
authors.initials: LL
authors.lastname: Zhai
authors.affiliation: Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China.
authors.forename: Y
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China. Electronic address: tzg567@163.com.
authors.forename: Z-G
authors.initials: ZG
authors.lastname: Tang
mesh_terms: D000328:Adult; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood; D002277:Carcinoma / Q000097:blood* / Q000737:chemistry / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D055806:Microvessels / Q000473:pathology; D008875:Middle Aged; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic; D010179:Pancreas / Q000098:blood supply / Q000737:chemistry; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000737:chemistry / Q000473:pathology*; D054464:Peroxiredoxins / Q000097:blood* / Q000737:chemistry; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000032:analysis; D011379:Prognosis; D012372:ROC Curve; D015996:Survival Rate; D015854:Up-Regulation; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D042461:Vascular Endothelial Growth Factor A; C515940:PRDX1 protein, human; D054464:Peroxiredoxins
keywords: Diagnosis; Maker; Pancreatic cancer; Peroxiredoxin-1; Prognosis; Prx-1